Cointime

Roivant Sciences

company

About

Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.

Highlights

Stock Symbol
nasdaq:ROIV
Total Funding Amount
$2.70B
Funding Rounds
6
Investors
15
Investments
9
Lead Investments
4

Details

Last Funding Type
Private Equity（PE）
Last Funding Money Raised
$93M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical,Product Research
Founded date
May 1, 2014
Number Of Employee
501 - 1000
Operating Status
Active
Stock Symbol
nasdaq:ROIV
Legal Name
Roivant Sciences Ltd.

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.

Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$2.70B
Roivant Sciences has raised a total of $2.70B in funding over 2 rounds. Their latest funding was raised on Oct 1, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 1, 2021 Post-IPO Equity $200M 9 — — Detail
Oct 1, 2021 IPO $611M — — — Detail
Nov 13, 2018 Private Equity（PE） $200M 7 Novaquest Capital Management
RTW Investments 		— Detail
Aug 9, 2017 Private Equity（PE） $1.10B 2 SoftBank Vision Fund — Detail
Jul 13, 2016 Private Equity（PE） $500M 1 Viking Global Investors — Detail
Show More

Investments

Number of Investments
Number of Lead Investments
9
4
Roivant Sciences has made 9 investments. Their most recent investment was on Dec 13, 2022, when Nesto raised $80M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 13, 2022 Nesto
Series C $80M Financial Services —
Dec 7, 2022 Lokavant
Series A $21M Artificial Intelligence —
Nov 3, 2021 Medallion
Series B $30M Health Care —
Nov 1, 2021 gen-t
Pre-seed $2M Biotechnology —
Aug 2, 2021 Immunovant
Post-IPO Equity $200M Biotechnology Yes
Show More

Investors

Number of Lead Investors
Number of Investors
5
15
Roivant Sciences is funded by 15 investors. Novaquest Capital Management and Dainippon Sumitomo Pharma are the most recent investors.
Investor Name Lead Investor Funding Round
Novaquest Capital Management Yes Private Equity（PE）
Dainippon Sumitomo Pharma — Post-IPO Equity
Eventide — Post-IPO Equity
Fidelity Management and Research Company — Post-IPO Equity
Palantir Technologies — Post-IPO Equity
Patient Square Capital — Post-IPO Equity
RTW Investments — Post-IPO Equity
SoftBank Capital — Post-IPO Equity
Suvretta Capital Management — Post-IPO Equity
Viking Global Investors — Post-IPO Equity
Show More

Employee Profiles

Number of Employee Profiles
22
Roivant Sciences has 22 current employee profiles, including Executive Benjamin Zimmer
Benjamin Zimmer
Executive
Eric Venker
Executive
Navneet Alag
Employee
Rakhi Kumar
Executive
Alex Gasner
Executive
Show More

Exits

Roivant Sciences has had 2 exits. Roivant Sciences most notable exits include Immunovant ,   Arbutus Biopharma

Date Company Name Exit Type Industry
Apr 14, 2020 Immunovant IPO Biotechnology Detail
Nov 26, 2010 Arbutus Biopharma IPO Biopharma Detail

Acquisition

Roivant Sciences has acquired 1 organizations. Their most recent acquisition was Silicon Therapeutics on Feb 26, 2021. They acquired Silicon Therapeutics for $450M.

Date Company Name
Industry Acquisition Type Price
Feb 26, 2021 Silicon Therapeutics
Biotechnology acquisition $ 450M Detail
Cointime
Content
Company